State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019

Mclornan, Donal; Yakoub-Agha, Ibrahim; Robin, Marie; Chalandon, Yves; Harrison, Claire N.; Kroger, Nicolaus

Type de document :

Article dans une revue scientifique: Article original

DOI :

10.3324/haematol.2018.206151

PMID :

30872371

URL permanente :

http://hdl.handle.net/20.500.12210/104830

Titre :

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019

Auteur(s) :

Mclornan, Donal [Auteur]
Yakoub-Agha, Ibrahim [Auteur]

Lille Inflammation Research International Center - U 995 [LIRIC]
Robin, Marie [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Chalandon, Yves [Auteur]
Harrison, Claire N. [Auteur]
Kroger, Nicolaus [Auteur]

Titre de la revue :

Haematologica

Nom court de la revue :

Haematologica

Numéro :

104

Date de publication :

2019-04-01

ISSN :

1592-8721

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, ...
Lire la suite >Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, although allogeneic hematopoietic stem cell transplantation remains the only curative approach. Improvements in donor selection, conditioning regimens, disease monitoring and supportive care have led to augmented survival after transplantation. Nowadays, there are comprehensive guidelines concerning allogeneic hematopoietic stem cell transplantation for patients with myelofibrosis. However, it commonly remains difficult for both physicians and patients alike to weigh up the risk-benefit ratio of transplantation given the inherent heterogeneity regarding both clinical course and therapeutic response. In this timely review, we provide an up-to-date synopsis of current transplantation recommendations, discuss usage of JAK inhibitors before and after transplantation, examine donor selection and compare conditioning platforms. Moreover, we discuss emerging data concerning the impact of the myelofibrosis mutational landscape on transplantation outcome, peritransplant management of splenomegaly, poor graft function and prevention/management of relapse.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Collections :

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-30T10:26:59Z
2024-01-31T12:36:13Z

Fichiers

8840-Article Text-63017-1-10-20200724.pdf
Non spécifié
Accès libre
Accéder au document

Ce document est diffusé sous licence Attribution-NonCommercial 3.0 United States

Numéro de version	Lien	Date de modification
2	20.500.12210/104830*	2024-01-31T12:33:51Z
1	20.500.12210/104830.1	2024-01-30T10:26:59Z

State-of-the-art review: allogeneic stem ...

BibTeX

CSV

Excel

RIS

Fichiers

Historique des modifications

State-of-the-art review: allogeneic stem ... BibTeX CSV Excel RIS

Fichiers

Historique des modifications

State-of-the-art review: allogeneic stem ...

BibTeX

CSV

Excel

RIS